Process Development of the Pyrazinecarboxamide Component of Gilteritinib, a FLT3 Inhibitor

已完结 10 由 wang 发布于 2024/5/26 19:30:02

DOI:10.1021/acs.oprd.4c00119
作者：Toshiyuki Sugimori, Takahiro Akiba
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：Gilteritinib (ASP2215) is an inhibitor of the mutated FMS-like tyrosine kinase 3 (FLT3) for the treatment of relapsed or refractory acute myeloid leukemia. Discovery chemistry identified a k

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Royal Society of Chemistry (RSC)Flexible transparent and hydrophobic SiNCs/PDMS coatings for anti-counterfeit applications